Roche's revenue growth doubles to 4.2% by H1 2025.
Fwd P/E expands to 18x by Q3 2024 on pipeline clarity.
Diagnostics growth boosts P/E to 17x by Q4 2024.
Recent Daily Analysis
— The glaring contradiction in Roche—a +95% DCF upside versus a 0/100 quality score and sector-lagging performance—reveals the market is no longer treating it as a diversified pharmaceutical company. Instead, it is being priced as a binary bet on a single, high-risk drug pipeline, likely in Alzheimer's. Our hypothesis is that the zero quality score reflects this extreme concentration risk, as perceived by quantitative funds. The implication is that the stock’s performance is now almost entirely decoupled from its profitable base business. If the next clinical trial data readout for its lead candidate is anything less than a decisive success, the stock will continue to stagnate, as the entire DCF-implied upside is contingent on this single event.